Giovanni Grignani, MD, medical oncologist, Candiolo Cancer Institute IRCCS, discusses the intended patient population for trabectedin (Yondelis) in the treatment of sarcoma.
Giovanni Grignani, MD
Advertisement
Articles by Giovanni Grignani, MD
Giovanni Grignani, MD, medical oncologist, Candiolo Cancer Institute IRCCS, discusses the future of treatments for patients with soft tissue sarcoma.
Giovanni Grignani, MD, medical oncologist, Candiolo Cancer Institute IRCCS, discusses the safety profile of trabectedin (Yondelis) in the treatment of sarcoma.
Giovanni Grignani, MD, medical oncologist, Candiolo Cancer Institute IRCCS, discusses some of the data seen thus far with trabectedin as a treatment for patients with sarcoma.
Advertisement
Latest Updated Articles
Dr. Grignani on the Role of Trabectedin in SarcomaFebruary 3rd 2017
Dr. Grignani on the Future of Treatments for SarcomaJune 7th 2017
Advertisement
Advertisement
Trending on OncLive
1
ctDNA Status Has Strong Prognostic Value, Outperforming pCR Status, in Early TNBC
2
The OncFive: Top Oncology Articles for the Week of 5/31
3
CELMoDs and Bispecifics Break Through Across Lymphomas and Leukemias at EHA 2026
4
From Toilet Cleaner to Thoracic Oncologist and Patient: How Ross Camidge Built a Life Worth Loving
5